Imexpharm Corporation reported VND2,205 billion (US$87.3 million) in net revenue for 2024, marking a 10.6% year-on-year ...

Venus Remedies has secured the renewal of its EU-GMP certification from Infarmed, Portugal, for its Cephalosporin, Carbapenem ...

Venus Remedies secures EU GMP renewal from Infarmed, strengthens European market presence: Our Bureau, Bengaluru Wednesday, January 22, 2025, 15:30 Hrs [IST] Venus Remedies has an ...

Venus Remedies secures renewed EU GMP certification for its manufacturing facility, enabling expansion in European and global ...

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces today the launch of the company's first German-cultivated medical cannabis product, ...

The rise in Venus Remedies share price came after the company announced the renewal of its European GMP certification by ...

The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable ...

Imexpharm Corporation has announced its 2024 financial results with net revenue reaching VND2,205 billion, up 10.6 percent year on year, driven by robust growth in ETC channel and high-quality ...

Venues remedies rallied 5.30% to Rs 310.95 after the company successfully renewed its European good manufacturing practices (GMP) certification by infarmed, the national health authority of Medicines ...

VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade cannabis manufacturing ...

HYTN will endeavour to amend its licenses and/or certificates, establish a stability program, and implement GMP-compliant processes tailored for vape cartridge production.